MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis

BACKGROUND: Recurrent respiratory papillomatosis (RRP) or laryngeal papillomatosis is a disease caused by papillomavirus infection. METHODS: In this phase I/II clinical trial, we evaluated the efficacy of the modified vaccinia Ankara (MVA) E2 virus in the treatment of RRP. Twenty‐nine patients (18 f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabo Beltran, Olga Rodriguez, Rosales Ledezma, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590416/
https://www.ncbi.nlm.nih.gov/pubmed/30605254
http://dx.doi.org/10.1002/hed.25477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590416/
https://www.ncbi.nlm.nih.gov/pubmed/30605254
http://dx.doi.org/10.1002/hed.25477

Ejemplares similares